PacBio Revenue Growth Masks Rising Losses Amid SPRQ-Nx Launch
Event summary
- PacBio reported Q4 2025 revenue of $44.6 million, a 14% year-over-year increase, and full-year revenue of $160 million, up 4% year-over-year.
- Consumables revenue reached a record $21.6 million in Q4 2025, while instrument revenue declined year-over-year to $17.3 million.
- The company reported a GAAP net loss of $40.4 million in Q4 2025 and a full-year GAAP net loss of $546.4 million, driven by increased operating expenses.
- PacBio completed the sale of its short-read sequencing assets, generating net cash proceeds of approximately $48.1 million.
- The company anticipates the launch of SPRQ-Nx, a new sequencing platform aimed at lowering sequencing costs, in 2026.
The big picture
PacBio's revenue growth is encouraging, but the substantial net losses highlight ongoing challenges in achieving profitability. The sale of short-read assets was intended to sharpen the company’s focus on long-read sequencing, but the continued high operating expenses suggest that scaling the business and achieving margin expansion will require significant execution. The upcoming SPRQ-Nx platform represents a critical inflection point, as its success will dictate PacBio’s ability to compete effectively and drive sustainable growth in the rapidly evolving genomics market.
What we're watching
- Cost Structure
- Whether PacBio can achieve the promised cost reductions with SPRQ-Nx and translate that into improved profitability remains a key risk, given the substantial net losses reported.
- Clinical Adoption
- The pace at which clinical adoption of PacBio’s long-read sequencing technology accelerates will determine the sustainability of consumables revenue growth and overall market penetration.
- Competition
- How PacBio’s competitors respond to the SPRQ-Nx launch and its impact on pricing will be critical in shaping the long-term competitive landscape of the long-read sequencing market.
Related topics